

Nicholas Lintzeris

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/109997/nicholas-lintzeris-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

3,432
citations

33
h-index

50
g-index

160
ext. papers

4,254
ext. citations

5
avg, IF

5.46
L-index

#	Paper	IF	Citations
147	Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.. <i>Drug and Alcohol Dependence</i> , 2022 , 234, 109388	4.9	0
146	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain.. <i>International Journal of Drug Policy</i> , 2022 , 105, 103708	5.5	
145	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021 , 116, 1482-1494	4.6	1
144	Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the PELICANS study.. <i>Epilepsy and Behavior</i> , 2021 , 127, 108496	3.2	2
143	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2021 , 100, 103492	5.5	2
142	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021 , 4, e213059	10.4	2
141	Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e219041	10.4	13
140	Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. <i>BMJ Open</i> , 2021 , 11, e044696	3	2
139	Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges. <i>Journal of Substance Abuse Treatment</i> , 2021 , 124, 108221	4.2	4
138	Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. <i>Addiction</i> , 2021 ,	4.6	7
137	Assessing the concurrent validity, inter-rater reliability and test-re-test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. <i>Addiction</i> , 2021 , 116, 1245-1255	4.6	2
136	The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial. <i>Journal of Sleep Research</i> , 2021 , 30, e13211	5.8	0
135	Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. <i>Drug and Alcohol Review</i> , 2021 ,	3.2	3
134	Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. <i>Drug and Alcohol Dependence</i> , 2021 , 227, 108959	4.9	5
133	Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. <i>Drug and Alcohol Review</i> , 2021 , 40, 567-571	3.2	8
132	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3092-3104	3.8	2
131	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials.. <i>Addiction Biology</i> , 2021 , e13125	4.6	0

130	Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. <i>Harm Reduction Journal</i> , 2020 , 17, 26	4.6	111
129	Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. <i>Drug and Alcohol Review</i> , 2020 , 39, 441-446	3.2	7
128	Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. <i>CNS Drugs</i> , 2020 , 34, 337-365	6.7	45
127	Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. <i>Drug and Alcohol Review</i> , 2020 , 39, 356-364	3.2	4
126	Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). <i>Harm Reduction Journal</i> , 2020 , 17, 37	4.6	29
125	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020 , 21, e79-e88	2.8	4
124	Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence-Reply. <i>JAMA Internal Medicine</i> , 2020 , 180, 163-164	11.5	
123	Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives. <i>Drug and Alcohol Review</i> , 2020 , 39, 55-65	3.2	4
122	Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. <i>Accident Analysis and Prevention</i> , 2020 , 148, 105784	6.1	7
121	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020 , 28, 100592	11.3	3
120	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. <i>Drug and Alcohol Dependence</i> , 2020 , 215, 108220	4.9	8
119	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020 , 10, e034389	3	6
118	Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study. <i>Pain Medicine</i> , 2020 , 21, 1188-1198	2.8	2
117	Detection of ΔTHC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. <i>Drug Testing and Analysis</i> , 2019 , 11, 1486-1497	3.5	16
116	Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. <i>Addiction</i> , 2019 , 114, 1416-1426	4.6	45
115	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. <i>Psychopharmacology</i> , 2019 , 236, 2713-2724	4.7	78
114	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019 , 20, 2450-2458	2.8	7
113	Regulatory and other responses to the pharmaceutical opioid problem. <i>Medical Journal of Australia</i> , 2019 , 210, 6-8.e1	4	15

112	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019 , 20, 758-769	2.8	7
111	Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision. <i>Internal Medicine Journal</i> , 2019 , 49, 1054-1055	1.6	7
110	Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2019 , 179, 1242-1253	11.5	37
109	Survey of Australian psychiatrists and psychiatry trainees knowledge about and attitudes towards medicinal cannabinoids. <i>Australasian Psychiatry</i> , 2019 , 27, 80-85	1.7	11
108	Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. <i>Journal of Addiction Medicine</i> , 2018 , 12, 234-240	3.8	12
107	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018 , 5, 155-166	23.3	22
106	Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs. <i>Drug and Alcohol Review</i> , 2018 , 37, 472-479	3.2	19
105	Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program. <i>Drug and Alcohol Review</i> , 2018 , 37, 464-471	3.2	28
104	Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke's Cognitive Examination-Revised, and Montreal Cognitive Assessment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018 , 40, 107-122	2.1	24
103	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. <i>Pain Medicine</i> , 2018 , 19, 533-540	2.8	23
102	An overview of take-home naloxone programs in Australia. <i>Drug and Alcohol Review</i> , 2018 , 37, 440-449	3.2	22
101	Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. <i>BMC Psychiatry</i> , 2018 , 18, 140	4.2	13
100	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018 , 8, e020723	3	9
99	Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16). <i>Medical Journal of Australia</i> , 2018 , 209, 211-216	4	41
98	Supervised Injectable Opioid Treatment for the Management of Opioid Dependence. <i>Drugs</i> , 2018 , 78, 1339-1352	12.1	13
97	Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2018 , 36, 67-78	4.4	16
96	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018 , 37, 887-896	3.2	3
95	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). <i>BMJ Open</i> , 2018 , 8, e020745	3	13

94	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health, The</i> , 2018 , 3, e341-e350	22.4	117
93	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. <i>Drug and Alcohol Review</i> , 2017 , 36, 311-316	3.2	3
92	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 587-591	2.6	28
91	Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. <i>Drug and Alcohol Dependence</i> , 2017 , 174, 181-191	4.9	21
90	An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. <i>Epilepsy and Behavior</i> , 2017 , 70, 334-340	3.2	44
89	Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 967-968	27.4	46
88	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2017 , 42, 1752-1765	8.7	132
87	Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2017 , 181, 132-139	4.9	19
86	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. <i>Mental Health and Physical Activity</i> , 2017 , 13, 57-67	5	4
85	Urinary cannabinoid levels during nabiximols (Sativex [®])-medicated inpatient cannabis withdrawal. <i>Forensic Toxicology</i> , 2017 , 35, 33-44	2.6	15
84	Alprazolam use and related harm among opioid substitution treatment clients - 12 months follow up after regulatory rescheduling. <i>International Journal of Drug Policy</i> , 2016 , 36, 104-11	5.5	15
83	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. <i>Drug and Alcohol Dependence</i> , 2016 , 162, 79-87	4.9	29
82	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016 , 35, 70-75 ^{3.2}	3.2	5
81	The Australian Treatment Outcomes Profile instrument as a clinical tool for older alcohol and other drug clients: A validation study. <i>Drug and Alcohol Review</i> , 2016 , 35, 673-677	3.2	9
80	Sleep Quality Among People Living With Chronic Noncancer Pain: Findings From the Pain and Opioids IN Treatment (POINT) Cohort. <i>Clinical Journal of Pain</i> , 2016 , 32, 380-7	3.5	8
79	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. <i>Pain</i> , 2016 , 157, 1489-1498	8	25
78	Substance use, health status and service utilisation of older clients attending specialist drug and alcohol services. <i>Drug and Alcohol Review</i> , 2016 , 35, 223-31	3.2	12
77	Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. <i>BMC Psychiatry</i> , 2016 , 16, 428	4.2	8

76	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016 , 159, 42-52	4.9	22
75	Recommendations for the Prevention, Detection, Treatment and Management of Prescription Opioid Analgesic Dependence: Outcomes From the Opioid Analgesic Dependence Education Nexus (OPEN) Meeting. <i>International Journal of Mental Health and Addiction</i> , 2016 , 14, 313-321	8.8	9
74	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016 , 35, 83-91	3.2	8
73	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015 , 151, 56-67	4.9	27
72	The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. <i>Pain</i> , 2015 , 156, 231-242	8	85
71	Screening for alcohol and substance use for older people in geriatric hospital and community health settings. <i>International Psychogeriatrics</i> , 2015 , 27, 157-66	3.4	19
70	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015 , 110, 226-37	4.6	18
69	Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). <i>Addiction</i> , 2015 , 110, 479-90	4.6	18
68	Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. <i>Drug and Alcohol Review</i> , 2015 , 34, 304-11	3.2	19
67	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015 , 58, 51-61	4.2	17
66	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015 , 34, 603-10	3.2	7
65	Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015 , 34, 623-9	3.2	5
64	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1321-33	2.6	4
63	The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. <i>Journal of Clinical Sleep Medicine</i> , 2015 , 11, 1153-62	3.1	12
62	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015 , 16, 1745-58	2.8	58
61	Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization. <i>Pain Medicine</i> , 2015 , 16, 356-66	2.8	77
60	Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. <i>European Respiratory Journal</i> , 2015 , 46, 1202-5	13.6	8
59	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. <i>Lancet Psychiatry</i> , 2015 , 2, 314-22 ²³⁻³		37

58	Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. <i>Drug and Alcohol Dependence</i> , 2015 , 147, 144-50	4.9	80
57	The diversion and injection of a buprenorphine-naloxone soluble film formulation. <i>Drug and Alcohol Dependence</i> , 2014 , 136, 21-7	4.9	39
56	Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. <i>Psychopharmacology</i> , 2014 , 231, 4623-36	4.7	24
55	Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study. <i>BMC Pharmacology & Toxicology</i> , 2014 , 15, 17	2.6	34
54	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014 , 142, 46-55	4.9	11
53	AuthorsSreply. <i>British Journal of Psychiatry</i> , 2014 , 204, 241-2	5.4	0
52	Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. <i>JAMA Psychiatry</i> , 2014 , 71, 281-91	14.5	155
51	Diversion of prescribed opioids by people living with chronic pain: results from an Australian community sample. <i>Drug and Alcohol Review</i> , 2014 , 33, 27-32	3.2	11
50	Validation and implementation of the Australian Treatment Outcomes Profile in specialist drug and alcohol settings. <i>Drug and Alcohol Review</i> , 2014 , 33, 33-42	3.2	53
49	Buprenorphine diversion and misuse in outpatient practice. <i>Journal of Addiction Medicine</i> , 2014 , 8, 327-338	3.8	4
48	Exercise increases plasma THC concentrations in regular cannabis users. <i>Drug and Alcohol Dependence</i> , 2013 , 133, 763-7	4.9	25
47	Correlates of pain in an in-treatment sample of opioid-dependent people. <i>Drug and Alcohol Review</i> , 2013 , 32, 489-94	3.2	6
46	An evaluation of the prescription of opioids for chronic nonmalignant pain by Australian general practitioners. <i>Pain Medicine</i> , 2013 , 14, 62-74	2.8	17
45	Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics. <i>Drug and Alcohol Review</i> , 2013 , 32, 566-73	3.2	14
44	An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. <i>Drug and Alcohol Review</i> , 2013 , 32, 495-503	3.2	9
43	Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. <i>British Journal of Psychiatry</i> , 2013 , 203, 341-9	5.4	50
42	The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. <i>Medical Journal of Australia</i> , 2013 , 199, 696-9	4	19
41	Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. <i>Medical Journal of Australia</i> , 2013 , 198, 80-1	4	29

40	Unplanned pregnancy and contraceptive use in women attending drug treatment services. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2012 , 52, 146-50	1.7	67
39	Reluctant to train, reluctant to prescribe: barriers to general practitioner prescribing of opioid substitution therapy. <i>Australian Journal of Primary Health</i> , 2012 , 18, 346-51	1.4	12
38	The health impacts of khat: a qualitative study among Somali-Australians. <i>Medical Journal of Australia</i> , 2011 , 195, 666-9	4	41
37	Investigating the effect on public behaviour of patients of a Medically Supervised Injectable Maintenance Clinic. <i>Drugs and Alcohol Today</i> , 2011 , 11, 204-209	1.4	1
36	Methadone and buprenorphine prescribing patterns of Victorian general practitioners: their first 5 years after authorisation. <i>Drug and Alcohol Review</i> , 2011 , 30, 355-9	3.2	8
35	Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?. <i>Drug and Alcohol Review</i> , 2011 , 30, 388-96	3.2	48
34	Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia?. <i>Drug and Alcohol Review</i> , 2011 , 30, 291-9	3.2	25
33	"Should I stay or should I go?" Coming off methadone and buprenorphine treatment. <i>International Journal of Drug Policy</i> , 2011 , 22, 77-81	5.5	40
32	Benzodiazepines, methadone and buprenorphine: interactions and clinical management. <i>American Journal on Addictions</i> , 2010 , 19, 59-72	3.7	79
31	The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. <i>Addiction</i> , 2010 , 105, 329-34	4.6	17
30	Commentary on Blanken et al. (2010): long-term heroin-assisted treatment-some more questions and answers. <i>Addiction</i> , 2010 , 105, 309-10	4.6	
29	Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. <i>Drug and Alcohol Review</i> , 2010 , 29, 469-74	3.2	5
28	The community impact of RIOTT, a medically supervised injectable maintenance clinic in south London. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2010 , 3, 248-259		3
27	Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets. <i>European Addiction Research</i> , 2010 , 16, 85-90	4.6	15
26	Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. <i>Lancet, The</i> , 2010 , 375, 1885-95	4.0	137
25	Why do patients report transferring between methadone and buprenorphine?. <i>Drug and Alcohol Review</i> , 2009 , 28, 686-7	3.2	9
24	Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria. <i>Australian and New Zealand Journal of Public Health</i> , 2009 , 33, 34-9	2.3	3
23	Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. <i>Journal of Substance Abuse Treatment</i> , 2009 , 37, 95-100	4.2	36

22	Prescription of heroin for the management of heroin dependence: current status. <i>CNS Drugs</i> , 2009 , 23, 463-76	6.7	24
21	Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. <i>Medical Journal of Australia</i> , 2009 , 191, 161-5	4	33
20	[Commentary] FUTURE CHALLENGES FOR HEROIN AND OTHER OPIOID SUBSTITUTION TREATMENT. <i>Addiction</i> , 2008 , 103, 967-968	4.6	12
19	The use of sublingual buprenorphine-naloxone for reversing heroin overdose: a high-risk strategy that should not be recommended. <i>Addiction</i> , 2008 , 103, 2065-6	4.6	5
18	Unplanned admissions to two Sydney public hospitals after naltrexone implants. <i>Medical Journal of Australia</i> , 2008 , 188, 441-4	4	20
17	Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. <i>Drug and Alcohol Dependence</i> , 2007 , 91, 187-94	4.9	62
16	Feasibility and acceptability of an intranasal diamorphine spray as an alternative to injectable diamorphine for maintenance treatment. <i>European Addiction Research</i> , 2006 , 12, 91-5	4.6	11
15	Effects of Pharmacotherapies for Opioid Dependence on Participants' Criminal Behaviour and Expenditure on Illicit Drugs: An Australian National Evaluation (NEPOD). <i>Australian and New Zealand Journal of Criminology</i> , 2006 , 39, 171-189	1.9	11
14	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. <i>Addictive Disorders and Their Treatment</i> , 2006 , 5, 155-164	0.5	10
13	Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 274-83	1.7	50
12	Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. <i>Addictive Behaviors</i> , 2005 , 30, 443-56	4.2	21
11	Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. <i>American Journal on Addictions</i> , 2004 , 13 Suppl 1, S29-41	3.7	45
10	Methadone syrup injection in Australia: a sentinel finding?. <i>Addiction</i> , 2003 , 98, 385-6	4.6	5
9	A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. <i>Addiction</i> , 2003 , 98, 1605-13	4.6	17
8	Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study. <i>Drug and Alcohol Dependence</i> , 2003 , 70, 287-94	4.9	22
7	Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. <i>Drug and Alcohol Dependence</i> , 2003 , 71, 49-55	4.9	40
6	A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. <i>Addiction</i> , 2002 , 97, 1395-404	4.6	75
5	Buprenorphine dosing regime in the management of out-patient heroin withdrawal. <i>Drug and Alcohol Review</i> , 2002 , 21, 39-45	3.2	16

4	Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. <i>Medical Journal of Australia</i> , 2002 , 176, 166-7	4	17
3	Trends in licit opioid use in Australia, 1984-1998: comparative analysis of international and jurisdictional data. <i>Medical Journal of Australia</i> , 2000 , 173, 524-7	4	18
2	Methadone injecting in Australia: a tale of two cities. <i>Addiction</i> , 1999 , 94, 1175-8	4.6	31
1	Cultural Adaptation and Psychometric Validation of the Australian Treatment Outcomes Profile for the Greek Population. <i>International Journal of Mental Health and Addiction</i> , 1	8.8	